Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR Antisense DNA with Radiation and Cetuximab in Head and Neck Cancer
NCT01592721Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Apr 2013
- Primary completion
- Feb 2022
- Modality
- Gene Editing, Gene Silencing, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BB-401 in squamous cell carcinoma of the head and neck (HNSCC), sponsored by UT Health San Antonio. Primary endpoints: Toxicity Rate at 1 year and Locoregional Progression-free Survival at 1 year. Started Apr 2013; status: completed.
02
Drugs
BB-401
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01592721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01592721.